Research

Moving Science Forward

eric hollander new photoDr. Eric Hollander, an internationally recognized psychiatrist and listed as one of America’s Top Doctors in Castle Connolly, is committed to bringing the latest improvements in autism
diagnosis and treatment.

Dr. Hollander has served as the principal investigator for a number of federal grants, including the NIH Greater New York Autism Center of Excellence, the NIMH Research Training Grant in Psychopharmacology and Outcomes Research, and an FDA funded multicenter treatment trial of pediatric body dysmorphic disorder. He was the principal investigator of the autism Clinical Trials Network, and Chair of the eight centers NIH STAART Autism Steering Committee.   He is principal investigator on new treatment studies in child and adult autism, and in childhood Prader Willi Syndrome.

Dr. Hollander has received a Research Scientist Development Award from the National Institute of Mental health to investigate the psychobiology of obsessive-compulsive and related disorders. He has received orphan drug grants from the Food and Drug Administration to study new treatments for body dysmorphic disorder, child/adolescent autism, and adult autism, and a grant from the National Institute of Drug Abuse for a study on the neurobiology of pathological gambling. He has received several grants from the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke, to develop treatments for borderline personality disorder, adolescent body dysmorphic disorder, and autism. Dr. Hollander has received two national research awards from the American Psychiatric Association and a Distinguished Investigator Award from the National Alliance for Research in Schizophrenia and Depression.

His unique expertise and leadership as the Chairman of ICare4Autism, Dr. Hollander has helped to increase our the organization’s impact and capabilities across the world through a series of conferences and workshops in the United States, Israel and soon in Mexico and in some countries of West Africa. 

He is Clinical Professor of Psychiatry and Behavioral Sciences and Director of the Autism and Obsessive Compulsive Spectrum Program, and the Depression and Anxiety Program at Albert Einstein College of Medicine and Montefiore Medical Center.  He is also Director of the Spectrum Neuroscience and Treatment Institute, whose mission is to provide state of the art, interdisciplinary, novel, and integrated treatments for Obsessive Compulsive Spectrum Disorders, Autism Spectrum Disorders, Anxiety Disorders and PANDAS Disorders in adults, adolescents and children.

Dr. Hollander and his team are conducting clinical trials  as follows: 

Autism and Obsessive Compulsive Spectrum Program

Current Studies

PI: Eric Hollander, MD

 

Curemark Study

Montefiore Medical Center, Albert Einstein College of Medicine is conducting a research study to examine if an investigational medication will help reduce the core symptoms of Autism. This is a 3-month research study where participants will either receive placebo (fake medicine) or investigational medication in the form of sprinkles to be placed on food. Participants must be 3 – 8 years old, be willing to undergo clinical and medical evaluations, and attend nine office visits. Collection of stool samples will also be required. Compensation for travel will be provided.

 

For more information on this research study, please call the Autism and Obsessive Compulsive Spectrum Program at 718-920-6732 or email spectrum@montefiore.org.

 

 

Vanilla Study

We’re learning about autism. Help us to learn about this disorder and possible future treatments by joining our clinical research study. You may be able to take part in this study if you:

  • ​Are a man aged 18-45 years with a diagnosis of autism spectrum disorder
  • Speak English
  • Have a caregiver willing to help you complete the study activities and answer questions from clinic staff. The VANILLA study will measure the effects of an investigation drug on social behavior, communication, and safety.

 

Contact us to learn more about the study. Call the Autism and Obsessive Compulsive Spectrum Program at 718-920-6732 or email spectrum@montefiore.org.

 

Children and Adolescents with Prader-Willi Syndrome

Montefiore Medical Center/Albert Einstein College of Medicine researchers are conducting a new study with the novel treatment, Intranasal Oxytocin, for children and adolescents with Prader-Willi Syndrome.

 

Your child may be eligible to participate if they:

  • Are between 5 to 18 years old
  • Meet the criteria for Prader-Willi Syndrome

Study details:

  • ​Minimum 12 weeks participation
  • Participants will receive $40 for each visit
  • Participants will be receive a study-related medical evaluation and study medication at no cost

Study will take place at Montefiore Medical Center (Bronx, NY).

 

Please contact us for more information concerning the treatment benefits and risks.

 

Autism and Obsessive Compulsive Spectrum Program

Director: Eric Hollander, MD

Call: 718-920-6732 or E-mail: spectrum@montefiore.org

 

Children and Adolescents with Prader-Willi Syndrome

Montefiore Medical Center/Albert Einstein College of Medicine researchers are conducting a new study with the novel treatment, Intranasal Oxytocin, for children and adolescents with Prader-Willi Syndrome. 

Your child may be eligible to participate if they:

  • Are between 5 to 18 years old
  • Meet the criteria for Prader-Willi Syndrome

Study details:

  • Minimum 12 weeks participation
  • Participants will receive $40 for each visit
  • Participants will be receive a study-related medical evaluation and study medication at no cost

Study will take place at Montefiore Medical Center (Bronx, NY).

Please contact them for more information concerning the treatment

benefits and risks.

Autism and Obsessive Compulsive Spectrum Program

Director: Eric Hollander, MD

Call: 718-920-6732 or E-mail: spectrum@montefiore.org

Curemark Study

Montefiore Medical Center, Albert Einstein College of Medicine is conducting a research study to examine if an investigational medication will help reduce the core symptoms of Autism. This is a 3-month research study where participants will either receive placebo (fake medicine) or investigational medication in the form of sprinkles to be placed on food. Participants must be 3 – 8 years old, be willing to undergo clinical and medical evaluations, and attend nine office visits. Collection of stool samples will also be required. Compensation for travel will be provided.

For more information on this research study, please call the Autism and Obsessive Compulsive Spectrum Program at 718-920-6732 or email spectrum@montefiore.org.

Vanilla Study

We’re learning about autism. Help us to learn about this disorder and possible future treatments by joining our clinical research study. You may be able to take part in this study if you:

  • Are a man aged 18-45 years with a diagnosis of autism spectrum disorder
  • Speak English
  • Have a caregiver willing to help you complete the study activities and answer questions from clinic staff. The VANILLA study will measure the effects of an investigation drug on social behavior, communication, and safety.

Contact them to learn more about the study. Call the Autism and Obsessive Compulsive Spectrum Program at 718-920-6732 or email spectrum@montefiore.org

Vayarin Study

Treatment study of a nutritional medicine vayarin (omega-3 fatty acid plus phosphatidylserine) in childhood autism spectrum disorder for children and adolescents with autism spectrum disorder.

Contact Eliana Bauman at ebauman@spectrumneuroscience.org